Thomas Gad | Founder, Chairman and President |
Claus Moller | Chief Executive Officer |
Bo Kruse | Chief Financial Office |
Alec Stranahan | Bank of America |
Robert Burns | H. C. Wainwright |
Boris Peaker | Cowen |
Benedict Shim | Canaccord Genuity |
Good day. And welcome to the Y-mAbs Therapeutics, Inc., 2019 Third Quarter Earnings Conference Call. Today's conference is being recorded.
Let me quickly remind you that the following discussion contain certain statements that are considered forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Because forward-looking statements involve risks and uncertainties, they are not guarantees of future performance, and actual results may differ materially from those expressed or implied by these forward-looking statements due to a variety of factors, including those risk factors discussed in the company's prospectus supplement dated October 29, 2019, and filed with the SEC on October 31st, 2019, and the company's Annual Report on Form 10-K for the fiscal year ended December 31st, 2018, as filed with the SEC on March 22, 2019.